Get started

Cannabis

MPXEF is bargain compared to CRON, TLRYMPXEF is now the third largest publicly traded cannabis operation by quarterly sales. Only WEED and ACB have higher sales. It leaves CRON, TLRY, and TRST in the dust when it comes to already-reality sales. It also trades at a nice discount to those other more famous names on a sales-basis. It also has not yet run much this MJ season. If you want something top-notch quality with very real revenues and profits, this seems like a good option. The pennant on the green flagpole is a continuation pattern. There are a million different ways you can draw this pennant and for some of them, it tried to break downward out of the pennant today. However, I like the strong bounce from that failed attempt by the bears. After taking a look at this, I'm buying some more at open. Here are a few tweets/articles with useful further info: - third largest by sales - comparison to peers price-wise - investor call and expansion plans - more peer comparison and SS - peer comparison
MLong
by HansMast
1
SHOP - The w[E]ed-[Commerce] solution from CANADA So you should know this buy now www.cbc.ca And if you are from Ontario and over 19 years old, I bet you also know what happens on October 17, 2018. www.ontario.ca Shopify Inc. (Nasdaq: SHOP) is a company that’s about to make billions from the end of marijuana prohibition without ever touching the leaf. It’s the online retailer – not Amazon.com Inc. (Nasdaq: AMZN) – that just inked a contract to provide an e-commerce platform for a major Canadian cannabis retailer. You see, when Canada goes fully legal later in summer 2018, pot companies will want to sell (and their customers will want to buy) their wares online. Makes sense. And the great news for investors in Shopify? The Ontario Cannabis Retail Corp. (OCRC) – the government agency in charge of sales in the province – is relying on Shopify, and only Shopify, to make it happen. That’s going to be a huge boon for cannabis investors. Ontario is home to 13.6 million people, with bustling Toronto and its financial sector at the heart of the province. That’s the perfect place to begin cashing in on Canada’s legal weed market, which Deloitte says could hit $8.7 billion over the next few years. But that’s really just the beginning for Shopify. This tech-forward company develops the kind of sophisticated software that allows small retailers to plug into e-commerce platforms like Amazon and sell their stuff. With Shopify’s platform, they can manage orders, collect sales dollars, and send out emails to buyers. Or, if they prefer to go it alone, Shopify can help small retailers build their own online storefront, handle multiple sales channels, and plug into social media for customer outreach. That business model alone qualifies this as a solid choice for investors. Its sales grew an average 85% over the past three years, compared to 26% growth for Amazon during that stretch. Now, OCRC has picked to exclusively use Shopify’s e-commerce platform for cannabis sales online. Shopify’s technology will also be used inside OCRC’s Ontario Cannabis Stores to process transactions and for digital kiosks displaying product information. And Ontario is just the “first mover” here. Many of Canada’s other nine provinces are likely to follow the leader here in choosing the home-grown Shopify (which is based in Ottawa) as their e-commerce partner. That could double Shopify’s total market opportunity there. In fact, Quebec province-based grower Hydropothecary Corp. has already chosen Shopify to help it sell medical marijuana online. Thanks to moves like the OCRC deal, Shopify’s total addressable market stands to exceed $50 billion… As a side note, just imagine if they integrate cryptocurrencies
TSX:SHOPLong
by johntuca
CANN - The one stop shop for legal weedWith General Cannabis Corp. (OTC: CANN), you are investing in the end of marijuana prohibition with a company that quite literally does it all. This Denver-based firm is like a weed mutual fund. It offers real estate and consulting services, dispensary security, and financing for cannabis companies. It also supports cannabis companies with brand development, product design services, and more. General Cannabis also grows cannabis for its own sales and helps new producers get started in the business. The company already has major clients in several states and is perfectly positioned to profit from the 15 states set to legalize marijuana this year. Anybody looking to enter the cannabis business at any level may have little choice but to do business with the firm. The security component of General Cannabis’ operations, Iron Protection Group (IPG), represents a compelling opportunity. You see, as long as federal cannabis drug statutes remain inconsistent with state cannabis laws, most banks – especially federally insured ones – refuse to handle transactions from cannabis retailers and growers. Those cannabis operators have been forced to rely almost exclusively on cash to transact business. And that’s left a tremendous need for security, which is where the IPG comes in. While banks will likely eventually start accepting commercial deposits from weed companies, a growing number of cannabis-based enterprises will still need to secure their stores and move their cash. And agricultural security, especially for highly remunerative strains, will remain a challenge for growers and a serious long-term growth opportunity for IPG. So right now, IPG’s business is tied to the planting and harvesting cycles of the crops. That cyclicality affects earnings, which wax and wane with the seasons. But that’s why smart companies diversify. General Cannabis can offset declining earnings in one division via growth in another. General Cannabis is essentially a “one-stop shop” for ambitious weed startups. One of its clients may begin working with Chiefton branding, then hire a Next Big Crop consultant, and then start working with IPG.
OTC:CANNLong
by johntuca
ACB see's a dip to $7.92 after announcement about MedReleaf" ACB announces it has received shareholder approval at a special meeting, held today, for the issuance of shares in consideration for the planned acquisition of MedReleaf Corp. ("MedReleaf"), a well-known Canadian Licensed Producer based in Markham, Ontario that delivers premium medical cannabis products to domestic and global markets, and compelling brands to the adult-use recreational market." Dillution, is a fact of company issuing shares for operating expenses, in this case it's a merger. There won't be a dillution, more shares will be issued and capital value of company will increase. So, currently 4.2bln, and it will be 7.6 bln, about the same as Canopy. It's the reason why Canopy is declining, because Aurora is bigger now. Leaders in the industry get higher p/e and share price as result... soon will be back at $9. There's some selling by Medreleaf are going on Aurora side, it's a reason, why we can't push back above 50 days. More Information about the Announcement here: Industry-leading scale: Funded capacity will increase to over 570,000 kg of high-quality cannabis per year, to be delivered through nine facilities in Canada and two in Europe Low production costs and industry-leading yields: Aurora's automated 'Sky Class' greenhouses are expected to deliver industry-leading efficiencies and ultra-low production costs of well below $1 per gram, delivering sustainably robust margins. MedReleaf's high-yield cultivation techniques are expected to further enhance productivity and reduce costs across the combined entity's facilities. International distribution: Aurora has established a strong and rapidly growing footprint in the international medical market. The combined entity is now well-positioned to rapidly gain market share in a number of significant markets. Most notable among these, is the European Union, which will have in excess of 400 million people following Brexit. Expanding brand leadership: Aurora, CanniMed and MedReleaf represent three well-established medical cannabis brands, and a growing portfolio of premium consumer and wellness brands including San Rafael '71, Woodstock, and AltaVie that are backed by detailed consumer and marketplace insights and advanced analytical frameworks. This brand leadership positions the combined entity well to drive accelerated growth through its existing distribution channels for the domestic medical and consumer markets, as well as the international medical markets. Scientific leadership: Each company is actively engaged in clinical trials and medical studies, which has resonated strongly with the international medical community, driving above-average prescription rates and referrals. Further, both companies have developed considerable expertise in cannabis plant genetics, enabling the development of new cultivars with specific traits for a variety of domestic and international markets, as well as strains optimized for automated cultivation. R&D: The combined company will have an industry leading Science and Research & Development team that includes approximately 40 PhDs and MScs. Both companies have a proven track record in developing new products, adopting new technology throughout the value chain, and integrating innovations from third parties. Combining these capabilities will accelerate product development and technology adoption, creating strong, defensible competitive advantages, including, management believes higher-margin offerings to drive above average profitability.
TSX:ACBLong
by zcsniper
3
CVSI - GRAND SLAM - Generational Opportunity - BUY!CVSI is a once in a generation opportunity. The company produces pharmaceutical grade CBD from cannabis. There are too many catalysts to name but the most recent one is that they have applied to move off the pink sheets to the NASDAQ. Also, Canada just legalized cannabis for recreational use and I believe the U.S. will be soon to follow. Lastly, CBD has a lot of promise for health and lifestyle products. CBD is literally being put in to make-up to dog treats. I came home the other night and my wife showed me the new dog treats for my aggressive basset hound. The dog treats had CBD as an ingredient and I checked Amazon to see the reviews. The product had 5 star reviews and everyone loved them. Also, CBD is legal from Hemp in the U.S. BUY BUY BUY! We are beginning the Cycle 3rd Wave now and are making new highs. -AB
OTC:CVSILong
by FibMarketWatch
4
ACBFF Aurora Cannabis INC. The bearish side of the story! :(Lets keep it simple?! I have charted ACBFF already with great results with a more positive outlook. I've came across another possibility that is short term bearish, but still long term bullish. I've explained most of the indicators in my previous chart, but here I just want to show levels, potential break outs and pull backs. I have labeled a small bounce area already for tomorrow or the next day, but ultimately will get to the $6 area again. This chart here shows what could happen if the wedge fails at that level, taking us to the 618 for what I believe could be the final bottom. The end of this longer failed wedge rolls right into new years, which could be a perfect time for the 618 level wedge to break out. Will update chart as time goes by, attempting to give clarity to the market. Corrections are healthy, health is never easy. Happy Trading, debating and speculating! FOLLOW for updates!
AShort
by ToddGreen
3
ACBFF Aurora Cannabis INC. Down before getting higher?Lets keep it super simple! I've been watching Aurora for some time now, and let me start off by saying this chart im posting is NOT in my favor with current position, but I cant just say its going up because I want it to, so lets look at what the chart has to say! Ill add more of course. Im in at @ 5.81 - 6.41, but sold on close today on the descending wedge formation @ 7.11. This chart is the 15 minute because at the end of this wedge in a wedge, you cannot see the details with the 4 hr or daily. We have seen this bounce respectively above the 5$ area, which is the blue line at the bottom. There is a false breakout of long term wedge at $8, and has fallen back into place. We have a descending wedge pattern into close today, which I didn't want, but it is what it is. Now if this wedge plays out through the end of the month, we should see another bounce at the bottom of the larger wedge at around 5.85 (labeled in green) You can see we have indications to sell since 8$ on the 4 hour, and have slight momentum change bearish, but to note NO sell signals on the daily. Ichimoku is also crossed bearish just slightly. I expect a small bounce around 6.75 back to maybe the 7.2 area, but will not play that trade, as ill be waiting for the full retrace to go long. Happy Trading, Debating and speculating! Never give legal advice! I want everyone to win!
AShort
by ToddGreen
The $CRON -ic is here to stay (Canada legalization)2018 is the year of legal weed in canada; listed on NYSE a few weeks ago as well so us americans can get some decent exposure too without having to fuss with the TSX or OTC nonsense. I see a breakout of the ichimoku cloud, a fractal breakout being called by williams trader beta, and also a trend breakout. Wouldn't surprise me if we dip and test the pennant again before we go up.. Decent RR here 3.5:1 (manage your risk accordingly) GL HF xoxo snoop
NASDAQ:CRONLong
by 420snoop
3